Delivering on the promise of science by advancing next‑generation ADCs
ADC Therapeutics is advancing next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. These proprietary PBD-based ADCs are expected to provide a novel way to treat hematologic cancers and solid tumors. In addition to our PBD technology, we are expanding our ADC platform with new antibody constructs and payloads. Our researchers intend to fully pursue all avenues to develop new and differentiated assets to address significant unmet medical needs and improve the lives of patients with cancer.